Search - tctmd.com

Displaying 101 - 120 of 142

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Four: Costs and Quality of Life Take Center Stage

Shelley Wood

September 29, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

Shelley Wood

September 27, 2019

Presentation TCT 2019

Therapy Choice of TAVR vs. SAVR

Presenter: Kendra Grubb

September 25, 2019

News Conference News TCT 2018

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

TCT Daily Staff

September 28, 2018

Presentation TCT 2018

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Presenter: Megan Coylewright

September 22, 2018

Presentation TCT 2018

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Presenter: Alfredo Trento

September 22, 2018

Presentation TCT 2018

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Presenter: Michael J. Mack

September 22, 2018

Presentation TCT 2018

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Presenter: Patrick T. O'Gara

September 22, 2018

Presentation TCT 2018

Counterpoint Volume Thresholds Distort Clinical Practice, Quality Metrics are the Priority and Have a Greater Impact on Outcomes

Presenter: Martin B. Leon

September 22, 2018

Presentation TCT 2018

Point Volume Threshold Increases are Needed to Assess Quality and Improve Clinical Outcomes

Presenter: Joseph E. Bavaria

September 22, 2018

Presentation TCT 2018

Opinion Concerns of TAVR Access for Underserved Populations

Presenter: Aaron Horne, Jr.

September 22, 2018

Presentation TCT 2018

Counterpoint Current and Future Demands Will Require TAVR Site Expansion

Presenter: Mark J. Russo

September 22, 2018

Presentation TCT 2018

Point Access Considerations Can be Managed Without Significant TAVR Site Expansion

Presenter: Carl L. Tommaso

September 22, 2018

Presentation TCT 2018

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Presenter: Charles J. Davidson, Jeffrey J. Popma, Matthew Summers

September 21, 2018

Presentation TCT 2018

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Presenter: Jose Armando Mangione

September 21, 2018

News Conference News TCT 2017

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Ashley Lyles

November 08, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Advertisement

TCT 2019 Day Four: Costs and Quality of Life Take Center Stage

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

TCT 2019 Day Two: Transcatheter Valves, New and Old

Therapy Choice of TAVR vs. SAVR

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Counterpoint Volume Thresholds Distort Clinical Practice, Quality Metrics are the Priority and Have a Greater Impact on Outcomes

Point Volume Threshold Increases are Needed to Assess Quality and Improve Clinical Outcomes

Opinion Concerns of TAVR Access for Underserved Populations

Counterpoint Current and Future Demands Will Require TAVR Site Expansion

Point Access Considerations Can be Managed Without Significant TAVR Site Expansion

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content